CAS Number22189-32-8
SynonymsMFCD00150886; spectogard; EINECS 244-554-3; Spectinomycin pentahydrate dihydrochloride; ACTINOSPECTACIN DIHYDROCHLORIDE; Spectinomycin HCL USP/BP; Spectinomycin dihydrochloride pentahydrate; SPECTINOMYCIN 2HCL; Trobicin (tn); SPECTINOMYCIN HCL; Spectinomycin hydrochloride; SpectinomycinHydrochloride
Molecular FormulaC14H36Cl2N2O12
Molecular Weight495.35
Purity98%
Boiling Point583.1ºC at 760 mmHg
Melting Point205-207° (dec)
Appearancepowder
EINECS244-554-3
Symbol
Signal WordWarning
| Chemical & Physical Properties | |
|---|---|
| CAS Number | 22189-32-8 |
| Catalog No. | 2A-9012495 |
| Chinese Name | 盐酸壮观霉素,五水合物 |
| Synonyms | MFCD00150886; spectogard; EINECS 244-554-3; Spectinomycin pentahydrate dihydrochloride; ACTINOSPECTACIN DIHYDROCHLORIDE; Spectinomycin HCL USP/BP; Spectinomycin dihydrochloride pentahydrate; SPECTINOMYCIN 2HCL; Trobicin (tn); SPECTINOMYCIN HCL; Spectinomycin hydrochloride; SpectinomycinHydrochloride |
| Molecular Formula | C14H36Cl2N2O12 |
| Molecular Weight | 495.35 |
| Purity | 98 |
| Boiling Point | 583.1ºC at 760 mmHg |
| Melting Point | 205-207° (dec) |
| Appearance | powder |
| Storage Condition | 2-8℃ |
| Application | Spectinomycin dihydrochloride pentahydrate is a broad-spectrum aminocyclodextrin antibiotic that can inhibit the growth of a variety of Gram-positive and Gram-negative organisms. |
| EINECS | 244-554-3 |
| HTC | 29419090 |
| PubChem ID | 24899581 |
| MDL Number | MFCD00150886 |
| SMILES | O.O.O.O.O.Cl.Cl.CN[C@@H]1[C@H](O)[C@H](NC)[C@H]2O[C@]3(O)[C@@H](O[C@H](C)CC3=O)O[C@@H]2[C@H]1O |
| InChI | 1S/C14H24N2O7.2ClH.5H2O/c1-5-4-6(17)14(20)13(21-5)22-12-10(19)7(15-2)9(18)8(16-3)11(12)23-14;;;;;;;/h5,7-13,15-16,18-20H,4H2,1-3H3;2*1H;5*1H2/t5-,7-,8+,9+,10+,11-,12-,13+,14+;;;;;;;/m1......./s1 |
| InChI Key | DCHJOVNPPSBWHK-UXXUFHFZSA-N |
| NACRES Code | NA.76 |
| UNSPSC | 12352207 |
| Hazard Symbols | Transport |
| MSDS | msds/12495_1_22189_32_8.pdf |
| Bioactivity | Spectinomycin dihydrochloride pentahydrate is a broad-spectrum aminocyclitol antibiotic that inhibits the growth of a variety of gram-positive and gram-negative organisms. Related Catalog Signaling Pathways >> Anti-infection >> Bacterial Research Areas >> Infection In Vitro Spectinomycin selectively inhibits protein synthesis in cells and in extracts of Escherichia coli. When added to an exponentially growing culture, spectinomycin (50 μg/mL) rapidly and reversibly inhibits growth of Escherichia coli. Amino acid incorporation is slowed immediately but RNA synthesis continued. In extracts of Escherichia coli B, spectinomycin inhibits polypeptide synthesis directed either by endogenous messenger RNA or by MS-2 bacteriophage RNA. Maximum inhibition (70 to 80%) is achieved at 1 μg/mL (3 μM). [1]. Spectinomycin blocks the translocation of peptidyl-tRNAs from the A-site to the P-site by inhibiting the binding of elongation factor G to the ribosome. Spectinomycin interacts specifically with the residues G1064 and 01192 in 16S rRNA and potentially change this molecule into an inactive conformation[2]. Spectinomycin acts as a mixed noncompetitive inhibitor for the td intron RNA with a Ki of 7.2 mM. The splicing inhibition by spectinomycin is dependent on pH changes and Mg2+ concentration, indicating electrostatic interactions with the intron RNA[3]. In Vivo Renal excretion is a major elimination pathway for spectinomycin. Following IV administration, approximately 55% of the drug is excreted into the urine in unchanged form. After IV administration of 10 mg/kg spectinomycin shows a peak plasma concentration of 37.8 μg/mL and a systemic exposure (area-under the curve AUC0-∞) of 15.7 μg/mL. Following single dose intramuscular administration, the overall elimination half-life of spectinomycin is 1.2 h in cattle, 1.0 h in sheep, 1.0 h in pigs, 1.65 h in chicken and 1.85 h in humans[4]. Animal Admin Rats: Spectinomycin (10 mg/kg) is administered intravenously to rats. Serial blood samples (approx. 250 μL) are collected pre-dose, and at 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 4.0, 6.0, 8.0, 12.0, 24.0, 36.0 and 48.0 h post-dose. Plasma is separated immediately by centrifugation (10,000g for 5 min at 4°C) and stored at −80°C until analysis. Urine samples are collected at an interval of 0-6, 6-12, 12-24, 24-36 and 36-48 h post-dose and stored at −80°C until analysis[4]. References [1]. Davies J, et al. Inhibition of protein synthesis by spectinomycin. Science. 1965 Sep 3;149(3688):1096-8. [2]. Brink MF, et al. Spectinomycin interacts specifically with the residues G1064 and C1192 in 16S rRNA, thereby potentially freezing this molecule into an inactive conformation. Nucleic Acids Res. 1994 Feb 11;22(3):325-31. [3]. Park IK, et al. Spectinomycin inhibits the self-splicing of the group 1 intron RNA. Biochem Biophys Res Commun. 2000 Mar 16;269(2):574-9. [4]. Madhura DB, et al. Pharmacokinetic profile of spectinomycin in rats. Pharmazie. 2013 Aug;68(8):675-6. Chemical & Physical Properties Boiling Point 583.1ºC at 760 mmHg Melting Point 205-207° (dec) Molecular Formula C14H36Cl2N2O12 Molecular Weight 495.348 Flash Point 306.4ºC Exact Mass 494.164520 PSA 175.66000 Vapour Pressure 5.05E-16mmHg at 25°C InChIKey UJEMGEUVWHFXGB-XYQGXRRISA-N SMILES CNC1C(O)C(NC)C2OC3(O)C(=O)CC(C)OC3OC2C1O.Cl.O Storage condition 2~8°C |
| Use of | Spectinomycin dihydrochloride pentahydrate is a broad-spectrum aminocyclitol antibiotic that inhibits the growth of a variety of gram-positive and gram-negative organisms. Properties Articles39 Name spectinomycin hydrochloride hydrate Synonym More Synonyms Biological Activity Description Spectinomycin dihydrochloride pentahydrate is a broad-spectrum aminocyclitol antibiotic that inhibits the growth of a variety of gram-positive and gram-negative organisms. Related Catalog Signaling Pathways >> Anti-infection >> Bacterial Research Areas >> Infection References [1]. Davies J, et al. Inhibition of protein synthesis by spectinomycin. Science. 1965 Sep 3;149(3688):1096-8. [2]. Brink MF, et al. Spectinomycin interacts specifically with the residues G1064 and C1192 in 16S rRNA, thereby potentially freezing this molecule into an inactive conformation. Nucleic Acids Res. 1994 Feb 11;22(3):325-31. [3]. Park IK, et al. Spectinomycin inhibits the self-splicing of the group 1 intron RNA. Biochem Biophys Res Commun. 2000 Mar 16;269(2):574-9. [4]. Madhura DB, et al. Pharmacokinetic profile of spectinomycin in rats. Pharmazie. 2013 Aug;68(8):675-6. Chemical & Physical Properties Exact Mass 494.164520 PSA 175.66000 InChIKey UJEMGEUVWHFXGB-XYQGXRRISA-N |
| Transport Info | Shipping Name: UN |
| MSDS Transport Info | Module 14. Shipping information 14.1 UN dangerous goods number European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.2 United Nations shipping name European Land Transport Dangerous Regulations: Non-dangerous goods IMDG Code: Non-dangerous goods International air transport dangerous goods regulations: non-dangerous goods 14.3 Transport hazard categories European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.4 Package group European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.5 Environmental hazards European Land Transport Danger Regulations: No International Maritime Danger Regulations International Air Transport Danger Regulations: No Marine pollutants (yes/no): No 14.6 Special reminder to users No data available |
| Related Products in Food Additives | ||
|---|---|---|
| Alitame | 80863-62-3 | 2A-9009107 |
| Carrageenan | 9000-07-1 | 2A-9009605 |
| Lenograstim | 135968-09-1 | 2A-9011147 |
| Nartograstim | 2A-302668 | 2A-9011585 |
| Spectinomycin HCL | 21736-83-4 | 2A-9012496 |
| Spectinomycin sulfate | 23312-56-3 | 2A-9012497 |
| Potassium metabisulfite | 16731-55-8 | 2A-9015405 |
| Potassium nitrate | 7757-79-1 | 2A-9015410 |
| Sodium Benzoate | 532-32-1 | 2A-9015644 |
| Browse all Food Additives products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS